Esketamine Hydrochloride
| Evidence Level: L5 | Predicted Indications: 50 |
Quick Overview
| Item | Value |
|---|---|
| Drug Name | Esketamine Hydrochloride |
| DrugBank ID | DB11823 |
| Brand Names (EU) | Spravato |
| Evidence Level | L5 |
| Predicted Indications | 50 |
| Top Prediction Score | 99.75% |
Approved Indication (EMA)
Spravato, in combination with a SSRI or SNRI, is indicated for adults with treatment-resistant Major Depressive Disorder, who have not responded to at least two different treatments with antidepressants in the current moderate to severe depressive episode.
Predicted New Indications
TxGNN model predictions for potential drug repurposing:
| Rank | Indication | Score | Source |
|---|---|---|---|
| 1 | dysthymic disorder | 99.75% | DL |
| 2 | anxiety disorder | 99.68% | DL |
| 3 | agoraphobia | 99.57% | DL |
| 4 | benign paroxysmal torticollis of infancy | 99.49% | DL |
| 5 | neurotic disorder | 98.85% | DL |
| 6 | neurotic depression | 97.83% | DL |
| 7 | melancholia | 97.74% | DL |
| 8 | vitamin B12-responsive methylmalonic acidemia | 97.32% | DL |
| 9 | obsessive-compulsive disorder | 97.31% | DL |
| 10 | Keppen-Lubinsky syndrome | 97.25% | DL |
| 11 | insomnia (disease) | 96.39% | DL |
| 12 | congenital isolated adrenocorticotropic hormone deficiency (disease) | 96.04% | DL |
| 13 | autosomal dominant slowed nerve conduction velocity | 95.54% | DL |
| 14 | schizoid personality disorder | 95.38% | DL |
| 15 | histrionic personality disorder (disease) | 95.38% | DL |
| 16 | schizotypal personality disorder | 95.38% | DL |
| 17 | paranoid personality disorder | 95.38% | DL |
| 18 | Ohdo syndrome and variants | 94.76% | DL |
| 19 | blepharophimosis - intellectual disability syndrome, Ohdo type | 93.47% | DL |
| 20 | narcissistic personality disorder | 91.36% | DL |
Showing top 20 of 50 predictions.
About TxGNN Predictions
Prediction Sources
| Source | Description |
|---|---|
| KG | Knowledge Graph - Network topology-based associations |
| DL | Deep Learning - Neural network score prediction |
Evidence Levels
| Level | Definition |
|---|---|
| L1 | Multiple Phase 3 RCTs / Systematic Reviews |
| L2 | Single RCT or multiple Phase 2 trials |
| L3 | Observational studies / Large case series |
| L4 | Preclinical / Mechanistic / Case reports |
| L5 | AI prediction only (current) |
Clinical Validation Needed
Research Use Only: These predictions are computational hypotheses that require clinical validation. They should NOT be used for clinical decision-making.
Next Steps for Validation
- Literature Review: Search PubMed for existing evidence
- Clinical Trial Search: Check ClinicalTrials.gov for ongoing studies
- Mechanistic Analysis: Evaluate biological plausibility
- Preclinical Studies: Conduct in vitro/in vivo validation
- Clinical Trials: Design and conduct human studies
Data Access
- FHIR API:
/fhir/ClinicalUseDefinition/ - CSV Download: All Predictions
- GitHub: yao-care/EuTxGNN
Citation
If using this data, please cite:
@article{huang2023txgnn,
title={A foundation model for clinician-centered drug repurposing},
author={Huang, Kexin and others},
journal={Nature Medicine},
year={2023},
doi={10.1038/s41591-023-02233-x}
}
Disclaimer: This report is for research purposes only and does not constitute medical advice. Drug repurposing predictions require rigorous clinical validation before any therapeutic application.